394 related articles for article (PubMed ID: 19411818)
1. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
2. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
[TBL] [Abstract][Full Text] [Related]
3. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
4. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu I; Ersoz HO
Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
[TBL] [Abstract][Full Text] [Related]
5. Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M
J Endocrinol Invest; 2008 Jun; 31(6):537-41. PubMed ID: 18591887
[TBL] [Abstract][Full Text] [Related]
6. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
7. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu İ; Ersoz HO
Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
[TBL] [Abstract][Full Text] [Related]
8. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
[TBL] [Abstract][Full Text] [Related]
9. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
Alioğlu B; Kılıç N; Şimşek E; Dallar Y
J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
[TBL] [Abstract][Full Text] [Related]
10. Blood coagulation and fibrinolysis in patients with hyperthyroidism.
Erem C; Ersoz HO; Karti SS; Ukinç K; Hacihasanoglu A; Değer O; Telatar M
J Endocrinol Invest; 2002 Apr; 25(4):345-50. PubMed ID: 12030606
[TBL] [Abstract][Full Text] [Related]
11. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.
Erem C; Kocak M; Nuhoglu I; Yılmaz M; Ucuncu O
Clin Endocrinol (Oxf); 2010 Oct; 73(4):502-7. PubMed ID: 20039901
[TBL] [Abstract][Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
[TBL] [Abstract][Full Text] [Related]
14. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
16. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery.
Manetti L; Bogazzi F; Giovannetti C; Raffaelli V; Genovesi M; Pellegrini G; Ruocco L; Iannelli A; Martino E
Eur J Endocrinol; 2010 Nov; 163(5):783-91. PubMed ID: 20696792
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma.
Ambrosi B; Sartorio A; Pizzocaro A; Passini E; Bottasso B; Federici A
Exp Clin Endocrinol Diabetes; 2000; 108(4):294-8. PubMed ID: 10961361
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
Liu YF; Hou N; Shi YJ; Li CX; Gao YJ; Liu LN
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1638-1642. PubMed ID: 37248064
[No Abstract] [Full Text] [Related]
19. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
Chhikara A; Sharma S; Chandra J; Nangia A
Indian J Pediatr; 2017 Jan; 84(1):25-30. PubMed ID: 27487812
[TBL] [Abstract][Full Text] [Related]
20. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
